Register Login

AIM IMMUNOTECH INC. (AIM)

(90% Positive) AIM IMMUNOTECH INC. (AIM) Announces Enrollment Update for results Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 10, 2026, 12:41 p.m.

    📋 AIM IMMUNOTECH INC. (AIM) - Clinical Trial Update

    Filing Date: 2026-08-10

    Accepted: 2026-08-10 08:40:31

    Event Type: Clinical Trial Update

    Event Details:

    AIM IMMUNOTECH INC. (AIM) Announces Clinical Trial Update AIM IMMUNOTECH INC. (AIM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, Initiatives
    • Diseases/Conditions: pancreatic cancer, Ebola OCALA
    • Clinical Stage: Phase 2 Trial, Phase 3
    • Collaboration: DURIPANC
    • Updated Timeline: Q1 2027, Q3 2027

    🔬 Clinical Development Pipeline (AIM IMMUNOTECH INC.):

    Product Type Development Stage Therapeutic Area Source
    Ampligen DRUG Phase PHASE3 Chronic Fatigue Syndrome ClinicalTrials.gov
    Rintatolimod Other Phase PHASE2 Prostate Adenocarcinoma ClinicalTrials.gov
    Cisplatin + CKM + Celecoxib + DC Vaccine Other Phase PHASE1 Cancer of Ovary ClinicalTrials.gov
    Cisplatin + celecoxib + DC vaccine Other Phase PHASE1 Cancer of Ovary ClinicalTrials.gov
    Recombinant Interferon Alfa-2b Other Phase PHASE2 Prostate Adenocarcinoma ClinicalTrials.gov
    Radical Prostatectomy Other Phase PHASE2 Prostate Adenocarcinoma ClinicalTrials.gov
    EC Aspirin Other Phase PHASE2 Prostate Adenocarcinoma ClinicalTrials.gov
    Debulking Procedure Procedure Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Celecoxib Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    αDC1 Vaccine Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Bioferon Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Cisplatin Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Paclitaxel Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    FluMist Other Phase PHASE1 Influenza, Human ClinicalTrials.gov
    Placebo Other Phase PHASE1 Influenza, Human ClinicalTrials.gov
    Poly I:Poly C12U 1250 ug Other Phase PHASE1 Influenza, Human ClinicalTrials.gov
    Poly I:Poly C12U 500 ug Other Phase PHASE1 Influenza, Human ClinicalTrials.gov
    Poly I:Poly C12U 200 ug Other Phase PHASE1 Influenza, Human ClinicalTrials.gov
    Poly I:Poly C12U 50 ug Other Phase PHASE1 Influenza, Human ClinicalTrials.gov
    Chemokine Modulation Therapy Drug Phase EARLY_PHASE1 Triple -Negative Breast Cancer ClinicalTrials.gov
    Biopsy Other Phase EARLY_PHASE1 Triple -Negative Breast Cancer ClinicalTrials.gov
    Chemokin Modulatory Regimen (20 MU/m2) Other Phase PHASE1 Colorectal Cancer ClinicalTrials.gov
    Chemokin Modulatory Regimen (10 MU/m2) Other Phase PHASE1 Colorectal Cancer ClinicalTrials.gov
    Chemokin Modulatory Regimen (5 MU/m2) Other Phase PHASE1 Colorectal Cancer ClinicalTrials.gov
    Placebo / Normal Saline Other Phase PHASE2 Post COVID-19 Condition ClinicalTrials.gov
    Durvalumab Other Phase PHASE1 Metastatic Pancreatic Cancer ClinicalTrials.gov
    Alferon LDO DRUG Phase PHASE2 HIV Infections ClinicalTrials.gov
    Poly I: Poly C12U (Rintatolimod) DRUG Preclinical Chronic Fatigue Syndrome ClinicalTrials.gov
    poly I-poly C12U DRUG Phase PHASE2 HIV Seropositivity ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AIM IMMUNOTECH INC.
    • Ticker Symbol: AIM

Search

News categories